Aktis Oncology is growing revenue at 123% year-over-year with favorable analyst sentiment and 37% upside to the consensus target — but quality metrics fall below the minimum threshold for entry, earnings have missed three of the past four quarters, and a 17% short interest adds downside risk if clinical momentum stalls.
Thesis pillars
- Quality Below Minimum Entry Threshold→Stable
- Exceptional Revenue Growth Rate→Stable
- Persistent Earnings Misses→Stable
- +1 more pillar — see the Why tab for full reasoning
Aktis Oncology, Inc. (AKTS) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.20: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: High short interest: 18%; Below-average business quality.
Aktis Oncology is a clinical-stage biotechnology company developing miniprotein radioconjugates that deliver alpha-emitting radioisotopes to solid tumors, with lead candidate [225Ac]Ac-AKY-1189 targeting Nectin-4-expressing cancers in a Phase 1b trial. The company has not... Read more
Sell if holding. Engine safety override at $28.20: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: High short interest: 18%; Below-average business quality. Chart setup: RSI 60 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 39d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-07-07Recent Developments — Aktis Oncology, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Monday's After-Market Session — benzinga Jul 6, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Monday's Intraday Session — benzinga Jul 6, 2026 neutral
- NEWS This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday — benzinga Jun 16, 2026 positive
- NEWS Raymond James Initiates Coverage On Aktis Oncology with Strong Buy Rating, Announces Price Target of $40 — benzinga Jun 16, 2026 positive
- NEWS Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday — benzinga Jun 12, 2026 positive
Generated 2026-07-07T09:31:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHpipelinelead product candidate [225Ac]Ac-AKY-118910-K Item 1A: 'Our business is highly dependent on our lead product candidate, [225Ac]Ac-AKY-1189, for the treatment of Nectin-4 expressing tumors.'
Material Events(8-K, last 90d)
- 2026-04-16Item 5.02LOWBoard appointed Glenn Gormley, MD, PhD as a Class I director effective April 15, 2026, and named him Co-Chair of the newly created Science and Technology Committee. Routine board appointment; no departure involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Volatile — 11.7% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.20: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: High short interest: 18%; Below-average business quality. Chart setup: RSI 60 mid-range, Bollinger mid-band. Prior stop was $24.70. Score 5.8/10, moderate confidence.
Take-profit target: $29.47 (+11.0% upside). Prior stop was $24.70. Stop-loss: $24.70.
Concentration risk — Pipeline: lead product candidate [225Ac]Ac-AKY-1189; Quality below floor (2.9 < 4.0).
Aktis Oncology, Inc. trades at a P/E of N/A (forward -16.4). TrendMatrix value score: 6.0/10. Verdict: Sell.
12 analysts cover AKTS with a consensus score of 4.3/5. Average price target: $34.
What does Aktis Oncology, Inc. do?Aktis Oncology is a clinical-stage biotechnology company developing miniprotein radioconjugates that deliver...
Aktis Oncology is a clinical-stage biotechnology company developing miniprotein radioconjugates that deliver alpha-emitting radioisotopes to solid tumors, with lead candidate [225Ac]Ac-AKY-1189 targeting Nectin-4-expressing cancers in a Phase 1b trial. The company has not generated product revenue and funds operations through equity financings and a May 2024 discovery collaboration with Eli Lilly, which paid a $60.0 million upfront fee and could contribute up to $1.2 billion in milestones. Aktis held $226.8 million in cash as of December 31, 2025, plus $335.3 million in IPO proceeds from its J